Daniel Barenboim, Parkinson's disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
Hosted on MSN21m
Ozzy Osbourne Can No Longer Walk Amid Parkinson's BattleOzzy Osbourne's health struggles will not prevent him from taking the stage one final time. Despite being unable to walk, the musician is set to participate in Back to the Beginning - a one-day music ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Sharon Osbourne has opened up about the declining health of her husband Ozzy Osbourne amid his ongoing battle with ...
GlobalData on MSN14h
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialResearchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback